

TABLE 190: ADVERSE EVENT

AUTHOR, YEAR, STUDY NAME	GENOTYPE	TREATMENT	n	N	%
Afdhal et al., 2014 ION-1	1	(6) SOF12 + LDV12	169	214	79%
		(7) SOF24 + LDV24	178	217	82%
		(10) SOF12 + LDV12 + RBV12	185	217	85%
		(11) SOF24 + LDV24 + RBV24	200	217	92%
Buti et al., 2014 OPTIMIZE	1	(32) T12 PR24-48 RGT q8	368	371	99%
		(33) T12 PR24-48 RGT q12	361	369	98%
Feld et al., 2014 SAPPHIRE-I	1	(15) PAR/RIT12 + OMB12 + DAS12 + RBV12	414	473	88%
Ferenci et al., 2014 PEARL-III	1b	(14) PAR/RIT12 + OMB12 + DAS12	140	209	67%
Ferenci et al., 2014 PEARL-IV	1a	(15) PAR/RIT12 + OMB12 + DAS12 + RBV12	92	100	92%
Fried et al., 2013 PILLAR	1	(1) PR48	75	77	97%
		(42) SIM12 PR24-48 RGT	76	77	99%
Gane et al., 2013-1 ELECTRON	2+3	(3) SOF12 + RBV12	10	10	100%
		(40) SOF12 + PR12	11	11	100%
Gane et al., 2013-3 ELECTRON	1	(3) SOF12 + RBV12	25	25	100%
Gane et al., 2014-1 ELECTRON	1	(10) SOF12 + LDV12 + RBV12	24	25	96%
Hassanein et al., 2015	4	(52) DCV12 + ASU12 + BEC12 (75 mg b.i.d.)	7	11	64%
		(53) DCV12 + ASU12 + BEC12 (150 mg b.i.d.)	8	10	80%
Jacobson et al., 2014 QUEST-1	1	(1) PR48	125	130	96%
		(42) SIM12 PR24-48 RGT	255	264	97%
Jacobson et al., 2011 ADVANCE	1	(1) PR48	354	361	98%
		(32) T12 PR24-48 RGT q8	361	363	99%
Kohli et al., 2015 NR	1	(6) SOF12 + LDV12	20	20	100%
Kowdley et al., 2013 ATOMIC	1	(40) SOF12 + PR12	51	52	98%
Kowdley et al., 2014 ION-3	1	(6) SOF12 + LDV12	149	216	69%
		(8) SOF8 + LDV8	145	215	67%
		(9) SOF8 + LDV8 + RBV8	165	216	76%
Lalezari et al. et al., 2015	1	(15) PAR/RIT12 + OMB12 + DAS12 + RBV12	35	38	92%
Lawitz et al., 2013 NEUTRINO	1+4+5+6	(40) SOF12 + PR12	310	327	95%
Lawitz et al., 2013 FISSION	2+3	(3) SOF12 + RBV12	220	256	86%
		(70) PR24	233	243	96%
Lawitz et al., 2014 LONESTAR	1a, 1b	(6) SOF12 + LDV12	8	19	42%
		(8) SOF8 + LDV8	9	20	45%

AUTHOR, YEAR, STUDY NAME	GENOTYPE	TREATMENT	n	N	%
		(9) SOF8 + LDV8 + RBV8	12	21	57%
Lawitz et al., 2013-1 PROTON	1	(1) PR48	26	26	100%
		(41) SOF12 PR24-48 RGT	46	47	98%
Lawitz et al., 2013-2 PROTON	2+3	(40) SOF12 + PR12	24	25	96%
Lawitz et al., 2015-1 C-WORTHY	1	(57) GRZ12 + ELB12 (50 mg q.d.)	17	29	59%
		(59) GRZ18 + ELB18 (50 mg q.d.)	25	31	81%
		(63) GRZ12 + ELB12 (50 mg q.d.) + RBV12	24	31	77%
		(65) GRZ18 + ELB18 (50 mg q.d.) + RBV18	28	32	88%
Manns et al., 2014 HALLMARK-DUAL	1b	(17) DCV24 + ASU24	176	205	86%
Manns et al., 2014 QUEST-2	1	(1) PR48	132	134	99%
		(42) SIM12 PR24-48 RGT	249	257	97%
Marcellin et al., 2011	1	(32) T12 PR24-48 RGT q8	81	82	99%
		(33) T12 PR24-48 RGT q12	79	79	100%
Molina et al., 2015-1+3+4 PHOTON-2	1+3+4	(4) SOF24 + RBV24	182	200	91%
Molina et al., 2015-2 PHOTON-2	2	(3) SOF12 + RBV12	17	19	89%
Osinusi et al., 2013 SPARE-1	1	(4) SOF24 + RBV24	9	10	90%
Osinusi et al., 2013 SPARE-2	1	(4) SOF24 + RBV24	24	25	96%
		(71) SOF24 + RBV (low dose) 24	21	25	84%
Osinusi et al., 2015	1	(6) SOF12 + LDV12	50	50	100%
Poordad et al., 2011 SPRINT2	1	(1) PR48	356	363	98%
		(46) B24 PR28-48 RGT	365	368	99%
Rodriguez-Torres et al., 2015	1+2+3+4	(40) SOF12 + PR12	16	23	70%
Sulkowski et al., 2015-1 C-WORTHY	1	(23) GRZ12 + ELB12 + RBV12	65	86	76%
		(57) GRZ12 + ELB12(50 mg q.d.)	38	43	88%
		(61) GRZ8 + ELB8(50 mg q.d.) + RBV8	26	30	87%
Sulkowski et al., 2015-2 C-WORTHY	1	(57) GRZ12 + ELB12 (50 mg q.d.)	15	30	50%
		(63) GRZ12 + ELB12 (50 mg q.d.) + RBV12	19	29	66%
Sulkowski et al., 2014-1 ^a	2+3	(3) SOF12 + RBV12	57	68	84%
Sulkowski et al., 2014-2	1	(4) SOF24 + RBV24	106	114	93%
Sulkowski et al., 2014	1	(19) DCV12 + SOF12	38	41	93%
Sulkowski et al., 2013-1+2 ^b	1	(1) PR48	22	22	100%
		(39) T12 PR48 q8	38	38	100%

AUTHOR, YEAR, STUDY NAME	GENOTYPE	TREATMENT	n	N	%
Sulkowski et al., 2013	1	(1) PR48	34	34	100%
		(50) B44 PR48	63	64	98%
Zeuzem et al., 2015-1+2+3 C-EDGE	1+4+6	(22) GRZ12 + ELB12	213	316	67%

ASU = asunaprevir; B = boceprevir; BEC = beclabuvir; b.i.d. = twice daily; CrI = credible interval; DAS = dasabuvir; DCV = daclatasvir; ELB = elbasvir; GRZ = grazoprevir; LDV = ledipasvir; OMB = ombitasvir; PAR = paritaprevir; PR = pegylated interferon plus ribavirin; q8 = every 8 hours; q12 = every 12 hours; q.d. = once daily; RBV = ribavirin; RD = risk difference; RGT = response-guided therapy; RIT = ritonavir; RR = relative risk; SIM = simeprevir; SOF = sofosbuvir; T = telaprevir; vs. = versus.

Note: Please refer to Treatment Regimen Nomenclature table for description of dosages.

^a Data for ineligible treatment for genotype 3, (3) SOF12 + RBV12, are included.

^b Data for ineligible participants who receive efavirenz-based antiretroviral and 1,125 mg of telaprevir every 8 hours are also included.